Dr. Jeffrey Sampson is a Research Fellow and Sr. Manager at Agilent Technologies where he focuses on Agilent’s longer-term strategic opportunities.
Dr. Sampson leads a diverse team of highly skilled professionals concentrating on applying physics, chemistry and biochemistry to advance life science measurement, intellectual property assessment, competitive market analysis as well as technical evaluation in support of Agilent’s licensing and acquisition opportunities. Dr. Sampson has also contributed to and managed DARPA sponsored projects focused on advanced nucleic synthesis technologies. Additionally, Dr. Sampson is a principal member of Agilent’s Early Stage Partnership program (ESP) where he performs opportunity evaluations and technical diligence working with early stage start-up companies. Dr. Sampson is on the Board of Purigen Biosystems which is also an Agilent ESP company. He has over 20 issued US patents in the fields of DNA and RNA synthesis and measurement and synthetic biology methods. Dr. Sampson holds a BS in chemistry from Butler University, a Ph.D. in biochemistry from the University of Illinois and a Postdoc and Senior Research Fellow at the California Institute of Technology.